Featured Research

from universities, journals, and other organizations

U.S. Researchers Show Cottonseed Drug Is Cancer Treatment Booster

Date:
October 4, 2004
Source:
European Organisation For Research And Treatment Of Cancer
Summary:
New research from the United States has opened up the prospect that gossypol – a drug refined from cottonseed oil and previously tried and abandoned as a male contraceptive – could boost the effectiveness of treatment for prostate tumours and possibly other common cancers as well.

Geneva, Switzerland: New research from the United States has opened up the prospect that gossypol – a drug refined from cottonseed oil and previously tried and abandoned as a male contraceptive – could boost the effectiveness of treatment for prostate tumours and possibly other common cancers as well.

Dr. Liang Xu, a research assistant professor at the University of Michigan, reported today (Friday 1 October) to the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva that gossypol has been shown by many groups to have anti-tumour activities.

But his team, under the leadership of Dr Marc Lippman and Dr Shaomeng Wang at the University's Comprehensive Cancer Center, has now demonstrated that a potential small molecule inhibitor of Bcl-2/xL proteins can boost the efficacy of radiotherapy and chemotherapy. They showed that the molecule, (-)-gossypol (minus gossypol)[2], inhibited the anti-apoptotic function of Bcl-2/xL in cells, and increased induction of apoptosis (programmed cell death) and made the tumours more sensitive to radiotherapy in human prostate tumours in mice. The study demonstrates for the first time that (-)-gossypol enhances the anti-tumour efficacy of radiation therapy both in vitro and in vivo with increased induction of apoptosis.

Dr. Xu explained: "The significance of this is that Bcl-2 and Bcl-xL proteins are over expressed in many cancers, making them resistant to drug and radiation treatment. So, it is not just prostate cancer that our findings are relevant to, but also other cancers with BcL-2/xL expression, such as those of the lung, breast, ovary, pancreas, skin, brain and head and neck, where (-)-gossypol may also sensitise cancer cells to chemo/radiotherapy."

He said that based on their cell and animal data the (-)-gossypol form of the drug was likely to be more active than the same doses of natural gossypol used in previous studies. Furthermore, their cell and animal data show that (-)-gossypol would make radiotherapy and chemotherapy more powerful and overcome the resistance to drug and radiation treatment caused by high levels of Bcl-2/xL.

Gossypol was researched as a male contraceptive in China as long ago as 1929 although the results were not published until 1957, but after large scale studies in the 1970s it was abandoned because some men remained infertile after stopping treatment. There were plans in Brazil in the 1990s to market the drug but these were shelved. In 1998 the World Health Organisation said that research on its use for contraception should be abandoned.

Gossypol is not the first drug investigated as a contraceptive to find a potential role in treating cancer.

Tamoxifen was first developed as a female contraceptive and failed, only to become the world's most successful breast cancer drug.

Will gossypol follow in the footsteps of tamoxifen? "There is a lot of research still to do, but we certainly hope so," said Dr. Xu. "The natural form of gossypol has been extensively tested in humans and is well tolerated for long-term use. If we use the more active form, (-)-gossypol, correctly and wisely – for example, in combination with radiation and/or chemotherapy – gossypol may soon find its new role in our fight against cancer."

Dr. Xu wishes to see the findings clinically tested soon and a Phase I trial is planned.


Story Source:

The above story is based on materials provided by European Organisation For Research And Treatment Of Cancer. Note: Materials may be edited for content and length.


Cite This Page:

European Organisation For Research And Treatment Of Cancer. "U.S. Researchers Show Cottonseed Drug Is Cancer Treatment Booster." ScienceDaily. ScienceDaily, 4 October 2004. <www.sciencedaily.com/releases/2004/10/041001091115.htm>.
European Organisation For Research And Treatment Of Cancer. (2004, October 4). U.S. Researchers Show Cottonseed Drug Is Cancer Treatment Booster. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2004/10/041001091115.htm
European Organisation For Research And Treatment Of Cancer. "U.S. Researchers Show Cottonseed Drug Is Cancer Treatment Booster." ScienceDaily. www.sciencedaily.com/releases/2004/10/041001091115.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins